Search Results - "Hoffknecht, P"

1300P Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab by Evers, G., Reitnauer, L.E., Christoph, D.C.C., Brueckl, W.M., Wiesweg, M., Glanemann, F., Webendoerfer, M., Kropf, C., Acker, F., Hund, A-C., Schütte, W., Hoffknecht, P., Kerkhoff, A., Mohr, M., Lenz, G., Frost, N., Overbeck, T.R., Sebastian, M., Bleckmann, A.

Get full text

CT-based software-supported prediction of the postoperative lung function after partial resection of the lung by Beyer, F, Heindel, W, Hoffknecht, P, Kuhnigk, J, Dicken, V, Lange, T, Thomas, M, Wormanns, D

“…The predicted postoperative forced exspiratory volume in one second (FEV (1)) is an important functional factor for predicting the operability of patients with…”
Get more information

49P EGFR exon 20 insertion mutations in patients with locally advanced or metastatic NSCLC in the German prospective, CRISP Registry real-world cohort (AIO-TRK-0315) by Griesinger, F., Sebastian, M., Bethge, A., Christopoulos, P., Hoffknecht, P., Waller, C., Benkelmann, R., Jänicke, M., Fleitz, A., Hanselmann, J., Hipper, A., Groth, A., Weichert, W., Nusch, A., Rauh, J., Fietz, T., Illmer, T., Depenbusch, R., Eberhardt, W.E.E., Thomas, M.

Get full text

1244P Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP) by Faehling, M., Schumann, C., Christopoulos, P., Hoffknecht, P., Alt, J., Horn, M., Eisenmann, S., Schlenska-Lange, A., Aries, S.P., Sackmann, S., Schuett, P., Steger, F., Christoph, D.

Get full text

1519P - Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315) by Sebastian, M., Eberhardt, W.E.E., Losem, C., Bernhardt, C., Maintz, C., Marschner, N.W., Jänicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Weichert, W., Hoffknecht, P., Grah, C., Rittmeyer, A., Griesinger, F., Thomas, M.

“…Treatment guidelines for metastatic non-small cell lung cancer recommend stratified treatment according to biomarker testing results. Here we used CRISP to…”
Get full text

1519PPatients with metastatic non-small cell lung cancer and PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315) by Sebastian, M, Eberhardt, W E E, Losem, C, Bernhardt, C, Maintz, C, Marschner, N W, Jänicke, M, Fleitz, A, Spring, L, Sahlmann, J, Karatas, A, Hipper, A, Weichert, W, Hoffknecht, P, Grah, C, Rittmeyer, A, Griesinger, F, Thomas, M

“…Abstract Background Treatment guidelines for metastatic non-small cell lung cancer recommend stratified treatment according to biomarker testing results. Here…”
Get full text

Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315) by Sebastian, M., Eberhardt, W.E.E., Losem, C., Bernhardt, C., Maintz, C., Marschner, N.W., Jänicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Weichert, W., Hoffknecht, P., Grah, C., Rittmeyer, A., Griesinger, F., Thomas, M.

Get full text

1364P Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C by Griesinger, F., Eberhardt, W.E.E., Hoffknecht, P., Metzenmacher, M., Wehler, T., Kokowski, K., Alt, J., Schütte, W., Jänicke, M., Fleitz, A., Zacharias, S., Hipper, A., Buller, M., Weichert, W., Groschek, M., Heyde, E. von der, Rauh, J., Dechow, T., Sebastian, M., Thomas, M.

Get full text

Die Primärtherapie des nichtkleinzelligen Lungenkarzinoms by Mohr, M., Kessler, T., Krug, U., Hoffknecht, P., Schmidt, L.H., Wiebe, K., Berdel, W.E., Wiewrodt, R.

“…Zusammenfassung Das Lungenkarzinom ist die häufigste zum Tode führende Tumorerkrankung. Nichtkleinzellige Lungenkarzinome („non-small cell lung cancer“; NSCLC)…”
Get full text

Preoperative chemotherapy with and without additional radiochemotherapy: benefit and risk for surgery of stage III non-small cell lung cancer by Semik, Michael, Riesenbeck, Dorothea, Linder, Albert, Schmid, Christof, Hoffknecht, Petra, Heinecke, Achim, Scheld, Hans H., Thomas, Michael

“…Objective: Multi-modality approaches are increasingly employed to improve prognosis in surgically treated stage III non-small cell lung cancer (NSCLC). Risk…”
Get full text

Combined modality treatment for locally advanced non-small cell lung cancer: preoperative chemoradiation does not result in a poorer quality of life by Schumacher, Andrea, Riesenbeck, Dorothea, Braunheim, Michael, Wewers, Dieter, Heinecke, Achim, Semik, Michael, Hoffknecht, Petra, Macha, Hans N, Klinke, Folker, Schmidt, Ernst-Wilhelm, Willich, Normann, Berdel, Wolfgang E, Thomas, Michael

“…The German Lung Cancer Cooperative Group (GLCCG) is assessing the impact of chemoradiation in addition to chemotherapy in the neoadjuvant treatment of stage…”
Get full text

First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer by Lange, Tobias, Müller-Tidow, Carsten, Serve, Hubert, Hoffknecht, Petra, Berdel, Wolfgang E, Thomas, Michael

“…Lung cancer has a high mortality rate and is often diagnosed in locally advanced or metastatic stages. A new therapeutic option for patients with non-small…”
Get more information

Signal transduction pathways as novel therapy targets in lung cancer by Reinmuth, Niels, Mesters, Rolf M., Bieker, Ralf, Hoffknecht, Petra, Berdel, Wolfgang E., Thomas, Michael

“…Cytotoxic therapy for lung-cancer patients has only moderately improved during the last decades. Simultaneously, efforts of intensive research to increase our…”
Get full text